Caribou Biosciences, Inc.
CRBU · NASDAQ
Market closed$1.65$-0.010000 (-0.60%)After hours $1.71 · +3.64%
Key statistics
Previous close$1.66
Open$1.64
Day high$1.69
Day low$1.60
52-week high$3.54
52-week low$1.38
Market cap163.65M
Volume1.44M
Average volume2.06M
P/E ratio-1.39
Forward P/E—
EPS-1.19
Dividend yield0.00%
Market context
Why it moved
CRBU edged slightly lower amid a lack of significant company-specific catalysts, with the modest decline reflecting routine profit-taking and broader sector caution in the biotech space.
What is happening
Recent company-specific developments and publisher coverage.
Pluang · June 29, 2026Caribou Biosciences CEO to speak at H.C. Wainwr...CRISPR Medicine News · June 18, 2026Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma ResponsesStock Titan · June 18, 2026Caribou Biosciences (NASDAQ: CRBU) holders reject officer exculpationInvesting.com · June 16, 2026H.C. Wainwright reiterates Caribou Biosciences stock rating at buyInvesting News Network · June 11, 2026Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association Annual MeetingInvesting News Network · June 11, 2026Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026Ad-hoc-news.de · May 14, 2026Caribou Biosciences stock (US1420381089): Q1 earnings beat and 4.4% surgeSimply Wall Street · May 13, 2026Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues Mt Newswire · June 11, 2026Caribou Biosciences Potential Non-Hodgkin Lymphoma Cell Therapy Shows 'Durable' Responses Benzinga · June 11, 2026Caribou Biosciences Reports Longer Follow Up Data For Ongoing CaMMouflage Phase 1 Trial Of CB-011, Off-The-Shelf BCMA-Targeted CAR-T Cell Therapy, Being Evaluated For r/r MM Benzinga · May 12, 2026Caribou Biosciences To Present Phase 1 CAR-T Therapy Data For vispa-cel And CB-011 At EHA 2026 Annual Meeting Benzinga · May 7, 2026Caribou Biosciences Q1 EPS $(0.26) Beats $(0.31) Estimate, Sales $2.397M Beat $2.241M Estimate Mt Newswire · March 31, 2026Caribou Biosciences Receives US FDA Advanced Therapy Status For Multiple Myeloma Drug Benzinga · March 31, 2026Caribou Biosciences Receives FDA's Regenerative Medicine Advanced Therapy Designation To CB-011 For Relapsed Or Refractory Multiple Myeloma Benzinga · March 9, 2026Evercore ISI Group Maintains Outperform on Caribou Biosciences, Raises Price Target to $13 Benzinga · March 5, 2026Insights into Caribou Biosciences Q4 Earnings